PFIZER, a global biopharmaceutical company, today announced the availability of Cibinqo (abrocitinib) and Staquis (crisaborole) as new additions to the atopic dermatitis treatment spectrum in Malaysia ...

Robert Sidbury MD, MPH, division head of dermatology at Seattle Children’s Hospital and professor in the department of pediatrics at University of Washington School of Medicine, explored the treatment ...

ATOPIC dermatitis (AD) is the most common chronic inflammatory skin condition, affecting up to 10% of adults and up to 20% of ...

Robert Sidbury MD, MPH explored the “long list” of treatment options in atopic dermatitis and how the treatment landscape has changed as a result in a video interview with Healio.“So long list – I ...

A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to ...

A medical research team has confirmed that ultrafine bubble showers significantly suppress inflammation in mice with atopic dermatitis due to external factors.

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a first-in-class ...

Panelists discuss how atopic dermatitis, a chronic inflammatory skin condition characterized by intense itching and recurring ...

Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16th edition of Skin Academy, a premier ...

Tralokinumab is effective in severe atopic dermatitis for up to 18 months, with patients who are naïve to some medications having faster benefits.

Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...

Asthma and atopic dermatitis are chronic inflammatory diseases of the airways and the skin, respectively, which affect hundreds of millions of children and adults globally. Most patients with asthma ...